Vivitra 150mg Injection

• Advanced and metastatic breast cancer
• Metastatic gastric cancer

Vivitra 150mg Injection is a strong anticancer medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.

Some common side effects include:

• Headache
• Fatigue
• Neutropenia (Low white blood cells)
• Nausea and Vomiting
• Rash
• Diarrhea
• Infections
• Fever
• Infusion reactions (e.g., chills, fever, pain)
• Anaemia (Low red blood cells)

Serious Side Effects of Injection are:

• Congestive heart failure (CHF)
• Pulmonary toxicity (Lung issues)
• Cardiomyopathy (Heart dysfunction)
• Severe infusion reactions (e.g., difficulty breathing, low blood pressure)

• Vivitra 150mg Injection is a prescription-based anticancer drug. It is advised to take this injection after consulting your healthcare expert.
• This medicine should be given intravenously by an experienced nurse or doctor. Please do not self-administer.

• Vivitra 150mg Injection contains Trustuzumab as an active ingredient which is a humanized monoclonal antibody.
• t works by blocking the action of HER2 receptor that promote growth and survival of cancer cells in breast and gastric cancer. Thereby, by selectively binds to HER2 it controls or inhibit the growth & multiplication of cancer cells to slow down the progression of disease.​​
  

• Jørgensen, J. T., Winther, H., Askaa, J., Andresen, L., Olsen, D., & Mollerup, J. (2021). A companion diagnostic with significant clinical impact in treatment of breast and gastric cancer. Frontiers in Oncology, 11, 676939.  https://pubmed.ncbi.nlm.nih.gov/34367962/   
• Meza-Junco, J., Au, H. J., & Sawyer, M. B. (2009). Trastuzumab for gastric cancer. Expert Opinion on Biological Therapy, 9(12), 1543-1551. https://pubmed.ncbi.nlm.nih.gov/19916733/
• Scheck, M. K., Hofheinz, R. D., & Lorenzen, S. (2024). HER2-positive gastric cancer and antibody treatment: state of the art and future developments. Cancers, 16(7), 1336. https://pubmed.ncbi.nlm.nih.gov/38611014/
• Shitara, K., & Ohtsu, A. (2016). Advances in systemic therapy for metastatic or advanced gastric cancer. Journal of the National Comprehensive Cancer Network, 14(10), 1313-1320. https://pubmed.ncbi.nlm.nih.gov/27697983/
• Tabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., ... & Kang, Y. K. (2018). Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. The Lancet Oncology, 19(10), 1372-1384. https://pubmed.ncbi.nlm.nih.gov/30217672/
• Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., ... & Kang, Y. K. (2017). Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. The lancet oncology, 18(5), 640-653. https://pubmed.ncbi.nlm.nih.gov/28343975/
• Okines, A. F., & Cunningham, D. (2010). Trastuzumab in gastric cancer. European journal of cancer, 46(11), 1949-1959.